Remove market-access views-analysis
article thumbnail

Deep Dive: Market Access

pharmaphorum

It’s fair to say this is the most interesting time ever for market access. A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how they can find a smoother path to market. Rethinking access barriers to innovation.

article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

Despite the market size for B-cell non-Hodgkin’s lymphoma (NHL) being at least five times that of ALL, NHL has a smaller pipeline of cell therapies. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Deep Dive: Market Access

pharmaphorum

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated challenge. Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. The post Deep Dive: Market Access appeared first on.

article thumbnail

The immediate future of DTC

World of DTC Marketing

As we look forward to 2021 DTC marketers should be noting the changes in consumer attitudes and the way they request new treatments. DTC marketers need to fall out of love with TV and think about how they translate awareness into brand objectives. It largely depends on how big your market is and where they get their health information.

Doctors 296
article thumbnail

ICSs – an opportunity to improve Patient & Market Access at a local level

pharmaphorum

However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. Francisco said in a statement that it offers “a market leading team [that] provides its customers with mission critical products and outstanding service.”

Radiology 110
article thumbnail

How does HTA for orphan drugs differ across Europe?

pharmaphorum

A new analysis from consulting firm CRA has honed in on the different challenges faced in four European markets – England, France, Germany and Scotland – and looked at how manufacturers can increase the chances of a successful appraisal. Source: CRA Analysis. Source: CRA Analysis.

Drugs 121